{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:03:28Z","timestamp":1784527408469,"version":"3.55.0"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapy has introduced a new spectrum of ICU-relevant complications in patients with cancer, including hyperinflammatory syndromes, neurotoxicity, severe pneumonitis, myocarditis, and overlapping infectious complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review the major life-threatening complications of cancer immunotherapy from an ICU perspective, focusing on recognition, differential diagnosis, and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>We discuss the critical illness patterns associated with CAR-T therapy, immune checkpoint inhibitors, and bispecific T-cell engagers using a syndrome-based framework. Key topics include cytokine release syndrome and HLH\/MAS, immune effector cell-associated neurotoxicity syndrome, respiratory failure related to pneumonitis and infection, cardiovascular emergencies such as myocarditis and arrhythmias, and other less common but ICU-relevant organ toxicities. We also summarize the major diagnostic conflicts in the ICU and propose general principles for organ support, immunomodulatory therapy, infection management, and multidisciplinary care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Immunotherapy-related critical illness is increasingly relevant in modern oncologic intensive care. Because these syndromes are often clinically overlapping yet potentially reversible, optimal management requires early ICU escalation, parallel diagnostic reasoning, and integrated supportive and syndrome-directed treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1841937","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:33:59Z","timestamp":1784525639000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Critical complications in cancer patients admitted to the ICU in the era of immunotherapy: recognition, differential diagnosis, and management"],"prefix":"10.3389","volume":"13","author":[{"given":"Di","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine, The first Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, The first Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1213\/ANE.0000000000005029","article-title":"Immune-related adverse events associated with immune checkpoint inhibitor therapy","volume":"132","author":"Ho","year":"2021","journal-title":"Anesth Analg."},{"key":"B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/CCM.0000000000004087","article-title":"Critical care management of toxicities associated with targeted agents and immunotherapies for cancer","volume":"48","author":"Gutierrez","year":"2020","journal-title":"Crit Care Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"101306","DOI":"10.1016\/j.blre.2025.101306","article-title":"Advances in the critical care management for patients with hematological malignancies","volume":"74","author":"Azoulay","year":"2025","journal-title":"Blood Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13613-019-0487-x","article-title":"Severe toxicity from checkpoint protein inhibitors: what intensive care physicians need to know?","volume":"9","author":"Lemiale","year":"2019","journal-title":"Ann Intensive Care."},{"key":"B5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.5811\/westjem.2020.1.45898","article-title":"Oncologic emergencies: immune-based cancer therapies and complications","volume":"21","author":"Long","year":"2020","journal-title":"West J Emerg Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/qjmed\/hcac258","article-title":"Intensive care unit requirements in patients treated with immune checkpoint inhibitors","volume":"116","author":"Cooksley","year":"2023","journal-title":"QJM."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e70264","DOI":"10.1111\/liv.70264","article-title":"Breaking barriers for intensive care admission in patients with advanced HCC on immunotherapy","volume":"45","author":"Fortuny","year":"2025","journal-title":"Liver Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.medin.2019.01.009","article-title":"Cytokine release syndrome: reviewing a new entity in the intensive care unit","volume":"43","author":"Garc\u00eda Roche","year":"2019","journal-title":"Med Intensiva."},{"key":"B9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.medine.2022.02.005","article-title":"Immune effector cell-associated neurotoxicity syndrome: a therapeutic approach in the critically Ill","volume":"46","author":"Suarez Montero","year":"2022","journal-title":"Med Intensiva."},{"key":"B10","doi-asserted-by":"publisher","first-page":"502135","DOI":"10.1016\/j.medin.2024.502135","article-title":"What should intensivists know about immune checkpoint inhibitors and their side effects?","volume":"49","author":"Zlatkov Aleksandrov","year":"2025","journal-title":"Med Intensiva."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.3390\/curroncol30050378","article-title":"Management and prevention of cellular-therapy-related toxicity: early and late complications","volume":"30","author":"Mucha","year":"2023","journal-title":"Curr Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s00063-025-01316-2","article-title":"Modern immunotherapy and emergency situations: toxicities of CAR T-cell therapies and BiTEs, their management, and their relevance in intensive care medicine","volume":"120","author":"Grans-Siebel","year":"2025","journal-title":"Med Klin Intensivmed Notfmed."},{"key":"B13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-024-01579-w","article-title":"Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma","volume":"17","author":"Sesques","year":"2024","journal-title":"J Hematol Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e006365","DOI":"10.1136\/jitc-2022-006365.","article-title":"Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis","volume":"11","author":"Moreno-Casta\u00f1o","year":"2023","journal-title":"J Immunother Cancer."},{"key":"B15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1177\/08850666231205264","article-title":"Primer on chimeric antigen receptor T-cell therapy-related toxicities for the intensivist","volume":"39","author":"Ong","year":"2024","journal-title":"J Intensive Care Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5811\/WESTJEM.20305","article-title":"Immune checkpoint inhibitor-associated pneumonitis: a narrative review","volume":"26","author":"Li","year":"2025","journal-title":"West J Emerg Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.bulcan.2019.09.003","article-title":"Myocarditis: uncommon but severe toxicity of immune checkpoint inhibitors","volume":"106","author":"Courand","year":"2019","journal-title":"Bull Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3892\/mco.2021.2282","article-title":"Cytomegalovirus pneumonia complicating immune checkpoint inhibitors-induced pneumonitis: a case report","volume":"14","author":"Badran","year":"2021","journal-title":"Mol Clin Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/anae.16453","article-title":"Immunotherapy on ICU: a narrative review","volume":"80","author":"Carter","year":"2025","journal-title":"Anaesthesia."},{"key":"B20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13613-020-00761-w","article-title":"Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit","volume":"10","author":"Joseph","year":"2020","journal-title":"Ann Intensive Care."},{"key":"B21","doi-asserted-by":"publisher","first-page":"114075","DOI":"10.1016\/j.ejca.2024.114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"G\u00e9raud","year":"2024","journal-title":"Eur J Cancer."},{"key":"B22","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00134-025-08155-x","article-title":"Life-threatening immune-related adverse events in the intensive care unit: a narrative review","volume":"51","author":"Pichon","year":"2025","journal-title":"Intensive Care Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e7302","DOI":"10.1002\/cam4.7302","article-title":"Severe immune-related adverse events due to immune checkpoint inhibitors leading to ICU admission: incidence, treatment patterns and survival outcomes","volume":"13","author":"Lin","year":"2024","journal-title":"Cancer Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13613-023-01122-z","article-title":"ICU admission for solid cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Toffart","year":"2023","journal-title":"Ann Intensive Care."},{"key":"B26","doi-asserted-by":"publisher","first-page":"E190","DOI":"10.1503\/cmaj.241384","article-title":"Bispecific antibody toxicities","volume":"197","author":"Britto","year":"2025","journal-title":"CMAJ."},{"key":"B27","doi-asserted-by":"publisher","first-page":"100061","DOI":"10.1016\/j.bneo.2024.100061","article-title":"Safety landscape of bispecific antibody therapy in non-hodgkin lymphoma: a systematic review and meta-analysis","volume":"2","author":"Fonseca","year":"2025","journal-title":"Blood Neoplasia."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1016\/j.ymthe.2025.03.048","article-title":"Non-relapse mortality with bispecific antibodies: a systematic review and meta-analysis in lymphoma and multiple myeloma","volume":"33","author":"Tix","year":"2025","journal-title":"Mol Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1097\/CCM.0000000000003258","article-title":"Management of the critically Ill adult chimeric antigen receptor-t cell therapy patient: a critical care perspective","volume":"46","author":"Gutierrez","year":"2018","journal-title":"Crit Care Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1164\/rccm.201810-1945ED","article-title":"Critical care management of chimeric antigen receptor T cell-related toxicity be aware and prepared","volume":"200","author":"Azoulay","year":"2019","journal-title":"Am J Respir Crit Care Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13613-022-01036-2","article-title":"The use of ICU resources in CAR-T cell recipients: a hospital-wide study","volume":"12","author":"Valade","year":"2022","journal-title":"Ann Intensive Care."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1219289","DOI":"10.3389\/fimmu.2023.1219289","article-title":"Risk factors and outcome of chimeric antigen receptor T-cell patients admitted to pediatric intensive care unit: CART-PICU study","volume":"14","author":"Caballero-Bell\u00f3n","year":"2023","journal-title":"Front Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13054-024-04851-0","article-title":"Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update","volume":"28","author":"Bellal","year":"2024","journal-title":"Crit Care."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e70069","DOI":"10.1002\/cncr.70069","article-title":"Cytokine release syndrome in solid tumors","volume":"131","author":"Synnott","year":"2025","journal-title":"Cancer."},{"key":"B36","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1213\/ANE.0000000000004201","article-title":"Next generation of cancer treatments: chimeric antigen receptor t-cell therapy and its related toxicities: a review for perioperative physicians","volume":"129","author":"Echeverry","year":"2019","journal-title":"Anesth Analg."},{"key":"B37","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.hoc.2025.02.005","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS)","volume":"39","author":"Lee","year":"2025","journal-title":"Hematol Oncol Clin North Am."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1664788","DOI":"10.3389\/fimmu.2025.1664788","article-title":"m-EASIX (better than EASIX) predicts severe car t-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsis","volume":"16","author":"Moreno-Casta\u00f1o","year":"2025","journal-title":"Front Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1007\/s00508-021-01948-2","article-title":"CAR T-cell therapy and critical care: a survival guide for medical emergency teams","volume":"133","author":"Messmer","year":"2021","journal-title":"Wien Klin Wochenschr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.1182\/bloodadvances.2020002592","article-title":"Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in patients receiving chimeric antigen receptor T-cell therapy","volume":"4","author":"Teachey","year":"2020","journal-title":"Blood Adv."},{"key":"B41","doi-asserted-by":"publisher","first-page":"7219","DOI":"10.1182\/blood-2024-207496","article-title":"Coagulation biomarker signature as a novel differential diagnostic tool for CRS\/ICANS and infection post-CAR-T therapy","volume":"144","author":"Brunner","year":"2024","journal-title":"Blood."},{"key":"B42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/CNQ.0000000000000302","article-title":"CAR T-cell-associated neurotoxicity: current management and emerging treatment strategies","volume":"43","author":"Rivera","year":"2020","journal-title":"Crit Care Nurs Q."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1007\/s00415-020-10237-3","article-title":"Neurological updates: neurological complications of CAR-T therapy","volume":"268","author":"Tallantyre","year":"2021","journal-title":"J Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.hemonc.2021.09.005","article-title":"Immune checkpoint inhibitor-induced pneumonitis: incidence, clinical characteristics, and outcomes","volume":"16","author":"Banavasi","year":"2023","journal-title":"Hematol Oncol Stem Cell Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jjcc.2025.09.010","article-title":"Cardiovascular-related hospital visits amongst oncology patients receiving immune checkpoint inhibitors: a population-based cohort study","volume":"87","author":"Dai","year":"2025","journal-title":"J Cardiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/diagnostics14161794","article-title":"Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review","volume":"14","author":"Lipe","year":"2024","journal-title":"Diagnostics."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e32240","DOI":"10.1097\/MD.0000000000032240","article-title":"Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: a case report and literature review","volume":"101","author":"Gao","year":"2022","journal-title":"Medicine."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e90424","DOI":"10.7759\/cureus.90424","article-title":"Multisystem immune-related adverse events following pembrolizumab: a critical care case of myocarditis, diabetic ketoacidosis, and CNS demyelination","volume":"17","author":"Janulevicius","year":"2025","journal-title":"Cureus."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e70058","DOI":"10.1002\/cnr2.70058","article-title":"Immunotherapy-induced type 1 diabetes mellitus causing diabetic ketoacidosis: a case report and review of current guidelines","volume":"7","author":"Disterhaft","year":"2024","journal-title":"Cancer Rep."},{"key":"B51","doi-asserted-by":"publisher","first-page":"8671530","DOI":"10.1155\/2020\/8671530","article-title":"Critical care admission of an HIV patient with diabetic ketoacidosis secondary to pembrolizumab","volume":"2020","author":"Cuenca","year":"2020","journal-title":"Case Rep Crit Care."},{"key":"B52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1530\/EDM-21-0130","article-title":"Myxoedema coma caused by immunotherapy-related thyroiditis and enteritis","volume":"2021","author":"Mc Donald","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J Endocr Soc."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2349796","DOI":"10.1080\/07853890.2024.2349796","article-title":"Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis","volume":"56","author":"Willyanto","year":"2024","journal-title":"Ann Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1182\/bloodadvances.2023011669","article-title":"Impact of diagnostic investigations in the management of CAR T-cell-related neurotoxicity syndrome","volume":"8","author":"Dumas","year":"2024","journal-title":"Blood Adv."},{"key":"B56","doi-asserted-by":"publisher","first-page":"29090","DOI":"10.1038\/s41598-024-80566-0","article-title":"EEG features and synek scale indicate severity of neurotoxicity in adult patients treated with CD19 CAR T-cell therapy","volume":"14","author":"Mao","year":"2024","journal-title":"Sci Rep."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1093383","DOI":"10.3389\/fcvm.2023.1093383","article-title":"Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: a single-center experience","volume":"10","author":"Xiao","year":"2023","journal-title":"Front Cardiovasc Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"100345","DOI":"10.1016\/j.hmedic.2025.100345","article-title":"When immunotherapy strikes the heart: a multimodal approach to immune checkpoint inhibitors induced myocarditis: a case series and literature review","volume":"14","author":"Basuoni","year":"2025","journal-title":"Medical Reports."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e252695","DOI":"10.1136\/bcr-2022-252695","article-title":"Pulmonary tumour thrombotic microangiopathy mimicking immunotherapy-associated pneumonitis","volume":"16","author":"McKenzie","year":"2023","journal-title":"BMJ Case Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12967-025-07646-1","article-title":"Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances","volume":"24","author":"Fatahichegeni","year":"2025","journal-title":"J Transl Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pccm.2024.12.001","article-title":"Clinical management of checkpoint inhibitor pneumonitis: focus, challenges, and future directions","volume":"3","author":"Xu","year":"2025","journal-title":"Chin Med J Pulm Crit Care Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1408586","DOI":"10.3389\/fcvm.2024.1408586","article-title":"Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity","volume":"11","author":"Wang","year":"2024","journal-title":"Front Cardiovasc Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00063-023-01057-0","article-title":"Side effects of immune checkpoint inhibitor therapy: what intensive care specialists need to know","volume":"119","author":"Buchtele","year":"2024","journal-title":"Med Klin Intensivmed Notfmed."},{"key":"B66","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11886-025-02232-9","article-title":"Leon Derby R, et al. Updates in diagnosis and treatment of immune checkpoint inhibitor myocarditis","volume":"27","author":"Hachem","year":"2025","journal-title":"Curr Cardiol Rep."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.3390\/cancers17223636","article-title":"When and for whom does intensive care unit admission change the prognosis in oncology? A scoping review","volume":"17","author":"Codru","year":"2025","journal-title":"Cancers."},{"key":"B68","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/hematology.2021000269","article-title":"Managing Therapy-associated neurotoxicity in children with all","volume":"2021","author":"Bhojwani","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"B69","doi-asserted-by":"publisher","first-page":"107958","DOI":"10.1016\/j.rmed.2025.107958","article-title":"Critical care considerations of chimeric antigen receptor","volume":"238","author":"Ponnapalli","year":"2025","journal-title":"(CAR) T-cell therapy Respir Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv."},{"key":"B71","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40266-024-01114-z","article-title":"Toxicity in older patients with cancer receiving immunotherapy: an observational study","volume":"41","author":"Tran Van Hoi","year":"2024","journal-title":"Drugs Aging."},{"key":"B72","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s11912-024-01528-3","article-title":"Immune checkpoint inhibitors in geriatric oncology","volume":"26","author":"Cook","year":"2024","journal-title":"Curr Oncol Rep."},{"key":"B73","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/jnci\/djaf373","article-title":"Impact of age and frailty on acute care use during immune checkpoint inhibitor treatment","volume":"118","author":"Eng","year":"2026","journal-title":"J Natl Cancer Inst."},{"key":"B74","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10555-024-10227-1","article-title":"Evolving strategies for addressing CAR T-cell toxicities","volume":"44","author":"Rankin","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1016\/S1470-2045(24)00404-2","article-title":"Management of immune checkpoint inhibitor-associated toxicities in older adults with cancer: recommendations from the international society of geriatric oncology (SIOG)","volume":"26","author":"Eochagain","year":"2025","journal-title":"Lancet Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"101742","DOI":"10.1016\/j.jgo.2024.101742","article-title":"Immunotherapy use in older adults with cancer with frailty: a young SIOG review paper","volume":"15","author":"Guven","year":"2024","journal-title":"J Geriatr Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jtct.2023.10.006","article-title":"Inspired symposium part 3: prevention and management of pediatric chimeric antigen receptor T cell-associated emergent toxicities","volume":"30","author":"McNerney","year":"2024","journal-title":"Transplant Cell Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann Neurol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1182\/bloodadvances.2022008119","article-title":"GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients","volume":"7","author":"Gust","year":"2023","journal-title":"Blood Adv."},{"key":"B81","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/jgs.15750","article-title":"Immune checkpoint inhibitors in real-world treatment of older adults with non-small cell lung cancer","volume":"67","author":"Muchnik","year":"2019","journal-title":"J Am Geriatr Soc."},{"key":"B82","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40266-024-01149-2","article-title":"Toxicity of cancer immunotherapies in older patients: does age make a difference?","volume":"41","author":"Cil","year":"2024","journal-title":"Drugs Aging."},{"key":"B83","doi-asserted-by":"publisher","first-page":"102829","DOI":"10.1016\/j.jgo.2025.102829","article-title":"Tolerability of immune checkpoint inhibitors for cancer treatment in frail, older patients","volume":"17","author":"Sheppard","year":"2026","journal-title":"J Geriatr Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"102936","DOI":"10.1016\/j.ctrv.2025.102936","article-title":"From ICI to ICU: a systematic review of patients with solid tumors who are treated with immune checkpoint inhibitors and admitted to the intensive care unit","volume":"136","author":"van Dijk","year":"2025","journal-title":"Cancer Treat Rev."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s40265-025-02243-4","article-title":"Long-term toxicities of immune checkpoint inhibitors","volume":"85","author":"Abraham","year":"2025","journal-title":"Drugs."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors: co-occurrence patterns and survival outcomes","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.cllc.2024.07.017","article-title":"Long-term clinical, radiological, and mortality outcomes following pneumonitis in nonsmall cell lung cancer patients receiving immune checkpoint inhibitors: a retrospective analysis","volume":"25","author":"Soto-Lanza","year":"2024","journal-title":"Clin Lung Cancer."},{"key":"B88","doi-asserted-by":"publisher","first-page":"730320","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systematic review and meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e091708","DOI":"10.1136\/bmjopen-2024-091708","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals","volume":"14","author":"L'Orphelin","year":"2024","journal-title":"BMJ Open."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1403658","DOI":"10.3389\/fonc.2024.1403658","article-title":"Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis","volume":"14","author":"Eldani","year":"2024","journal-title":"Front Oncol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"101488","DOI":"10.1016\/j.mcpro.2025.101488","article-title":"Plasma proteome-driven liquid biopsy for individualized monitoring and risk stratification of immune-related adverse events in checkpoint immunotherapy","volume":"25","author":"Yan","year":"2026","journal-title":"Mol Cell Proteomics."},{"key":"B92","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jjco\/hyaf200","article-title":"Efficacy and safety of immune checkpoint inhibitor rechallenge following immune-related adverse events: a review","volume":"56","author":"Mizuno","year":"2026","journal-title":"Jpn J Clin Oncol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jtct.2023.09.008","article-title":"Long-term survivors after failure of chimeric antigen receptor t cell therapy for large B cell lymphoma: a role for allogeneic hematopoietic cell transplantation? A German lymphoma alliance and German registry for stem cell transplantation analysis","volume":"29","author":"Derigs","year":"2023","journal-title":"Transplant Cell Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1158\/1078-0432.CCR-24-0414","article-title":"A 5-year follow-up clinical study of the b-cell maturation antigen chimeric antigen receptor T-cell therapy HDS269B in patients with relapsed or refractory multiple myeloma","volume":"30","author":"Chen","year":"2024","journal-title":"Clin Cancer Res."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1841937\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:34:01Z","timestamp":1784525641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1841937\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":94,"alternative-id":["10.3389\/fmed.2026.1841937"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1841937","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"article-number":"1841937"}}